Lantern Pharma Completes Targeted Enrollment for Phase 2 HARMONIC Trial in Japan Ahead of Schedule

Lantern Pharma (NASDAQ: LTRN), a pioneer in AI-driven oncology drug development, has announced the completion of targeted enrollment for its Phase 2 HARMONIC clinical trial in Japan ahead of schedule. This trial, focusing on never-smoker non-small cell lung cancer (NSCLC) patients who have progressed after tyrosine kinase inhibitors, has enrolled 10 patients across five sites, including the National Cancer Center Japan. The trial evaluates the efficacy of LP-300 in combination with carboplatin and pemetrexed.

The early completion of enrollment in Japan underscores the company's successful international expansion strategy, particularly in regions with a higher prevalence of never-smoker NSCLC, such as Japan and Taiwan. Lantern Pharma's CEO, Panna Sharma, highlighted this achievement as a validation of the company's approach to addressing unmet medical needs in oncology through its proprietary RADR(R) platform. The global trial aims to enroll approximately 90 patients, building on promising early U.S. data that showed an 86% clinical benefit rate, including a durable complete response lasting nearly two years.

This development is significant for the oncology field, as it represents a step forward in the personalized treatment of NSCLC, particularly for never-smokers, a demographic that has been historically underserved. The success of the HARMONIC trial could pave the way for new, effective treatment options for this patient group, potentially improving survival rates and quality of life. For more information on Lantern Pharma's innovative approach to cancer therapy, visit https://ibn.fm/IcDma.

The progress of the HARMONIC trial also highlights the growing role of AI and machine learning in drug development, with Lantern Pharma's RADR(R) platform leveraging over 100 billion oncology-focused data points to accelerate the discovery and development of targeted cancer therapies. This approach not only reduces the cost and time associated with traditional drug development but also increases the precision and effectiveness of treatments, offering hope to patients worldwide.